Psoriasis

Brad Glick, DO, FAOCD, highlights topical therapy as a targeted treatment of plaque psoriasis.

Benjamin Lockshin, MD, FAAD, comments on how the evolution of the pathophysiology of plaque psoriasis has led to more targeted therapies to treat the disease.

The intention is to expedite the development and review of the drug helping adults with generalized pustular psoriasis.

Inhibitor etanercept alleviated pathological changes and inflammation in induced psoriasis.

Oral vitamin D supplementation does not appear to have an effect on disease severity for those with low 25-hydroxyvitamin D (25[OH]D) levels.

Researchers compiled future research directions and therapeutic and clinical developments in psoriasis.

This will be the first clinical study in dermatology to assess patients’ wellbeing as a primary endpoint.

It has been hypothesized that some lipid-lowering drugs are disease-modifying for psoriasis, and the use of lipid-lowering drugs in the management of psoriasis symptoms is currently being explored

An expert in dermatology shares his thoughts on the educational and unmet needs in the identification and management of patients with GPP.

Dr David Kaplan discusses the current treatment options for GPP; highlighting the long time to treatment repose, need for combination treatment, and of standard of care guidelines.

David Kaplan, MD, provides an overview of generalized pustular psoriasis, and comments on his differential diagnosis process and key symptomology.

AbbVie announced study results demonstrating efficacy in patients with a history of previous interleukin-17 inhibitor therapy.

Researchers say the impacts may be more harmful than those caused by industrial air pollutants.

Dr Raj Chovatiya discusses a recently approved therapeutic agent, spesolimab, as a valuable addition to the GPP treatment landscape.

An expert dermatologist reviews the currently available agents for treatment of GPP and highlights the unmet needs in this space.

Raj Chovatiya, MD, PhD, provides an overview of the factors he uses to lead to a diagnosis of generalized pustular psoriasis (GPP).

An expert in dermatology shares his insights into the management considerations with traditionally utilized treatments for generalized pustular psoriasis and discusses the impact of a recent approval in this space.

Dr Michael Payette discusses the patient QoL impacts and burden of generalized pustular psoriasis.

Michael Payette, MD, MBA, FAAD provides an overview of generalized pustular psoriasis, highlighting the challenges in the diagnosis of patients with this condition.

Pregnant women with atopic dermatitis and psoriasis may require special treatment considerations.

Prior use of biologics in patients with plaque psoriasis may not impact the efficacy of risankizumab treatment.

What can you do when a medication for psoriasis yields a suboptimal response? New data presented at the 2023 AAD Annual Meeting provides valuable insight on next steps for treatment.

Researchers observed no difference in rate ratios between a 2009 to 2015 cohort and a 2016 to 2021 cohort.

JNJ-2113 met primary endpoints in the FRONTIER 1 clinical trial.

Linda Stein Gold, MD, and Jennifer Soung, MD, discuss available nonsteroidal treatment options for plaque psoriasis in this DermView series recap.

Aaron Farberg, MD, and Jeffrey Crowley, MD, take a closer look at the management and treatment of generalized pustular psoriasis.

Linda Stein Gold, MD, clears up confusion regarding various treatment options for patients with mild to moderate forms of the disease.

An expert dermatologist reviews generalized pustular psoriasis in 2 patients and how he would approach treatment and management.

Over the last few decades, genetic research has opened doors to improve the treatment of immune-mediated conditions like psoriasis, but there are still questions about how these diseases are triggered at the cellular level.

Highly effective medications for severe disease are expensive and administered invasively, while the development of treatments for milder disease has lagged, a new review on psoriasis clinical trials concludes.